{
    "nct_id": "NCT04931342",
    "official_title": "A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors",
    "inclusion_criteria": "* Persistent or recurrent EOC that meets the following criteria: Histologically confirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, including but not limited to low-grade serous ovarian carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma, undifferentiated carcinoma, seromucinous carcinoma, malignant Brenner tumors, Grades 1 or 2 endometrioid carcinoma, mesonephric-like adenocarcinoma and small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Disease that is not amenable to curative surgery\n* Measurable disease (at least one target lesion) according to RECIST v1.1\n* Previous treatment with one to four lines of therapy, at least one of which was platinum-based. Hormonal therapy does not count as a line of therapy.\n* Platinum-resistant disease, defined as disease progression during or within 6 months of last platinum therapy, with the following exception: Participants with primary platinum-refractory disease are excluded.\n* Submission of a representative tumor specimen that is suitable for next-generation sequencing (NGS) testing and estrogen receptor immunohistochemistry (ER IHC) to determine treatment arm assignment and for central pathology review.\n* Submission of the local pathology report and, if available, any associated stained slides that supported the local diagnosis of the histology (to be used for central pathology review)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs (if applicable)\n* In addition to the general inclusion criteria above, participants must meet all of the arm-specific inclusion criteria for the respective arm\n\nGeneral\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant or breastfeeding, or intending to become pregnant or breastfeed during the study\n* Primary platinum-refractory disease, defined as progression during or within 4 weeks after the last dose of the first-line platinum treatment\n* Histologic diagnosis of high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer\n* Current diagnosis of solely borderline epithelial ovarian tumor\n* Current diagnosis of non-epithelial ovarian tumors\n* Current diagnosis of synchronous primary endometrial cancer\n* Prior history of primary endometrial cancer, with the following exception: a prior diagnosis of primary endometrial cancer is permitted if it meets all of the following conditions: Stage IA, no lymphovascular invasion, International Federation of Gynecology and Obstetrics Grade 1 or 2, not a high-grade subtype.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Symptomatic, untreated, or actively progressing CNS metastases\n* Severe infection within 4 weeks prior to initiation of study treatment\n* Treatment with chemotherapy, radiotherapy, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, or investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with hormonal therapy within 14 days prior to initiation of study treatment\n* In addition to the general exclusion criteria above, participants can not meet any of the arm-specific exclusion criteria for the respective arm",
    "miscellaneous_criteria": ""
}